Investor Relations

Clear, current information for shareholders, investors and partners.

EXACT Therapeutics is a clinical-stage biotechnology company developing Acoustic Cluster Therapy (ACT®), a targeted approach designed to improve the delivery of cancer treatments.

Shareholder information

Practical information for shareholders, including information about the delisting process and key company documents.

View shareholder information

Sign up for shareholder updates

Receive the latest company news, financial updates and other relevant shareholder information by email.

Company at a glance

  • Focus: Oncology
  • Technology: Acoustic Cluster Therapy (ACT®)
  • Lead programme: PS101
  • Corporate status: Privately Held Norwegian Company

Latest update

First half 2026 interim report

3 September 2026
EXACT Therapeutics announced its first half 2026 interim results.

Read the interim report

Financial reports

2026

2025

2024

Older financial reports

Company presentations and webcasts

2026

2024

General meetings

Annual General Meeting 2026

Annual General Meeting 2025

Annual General Meeting 2024

Extraordinary General Meetings

Older AGM

Corporate governance

  • Annual and extraordinary general meeting documents
  • Articles of association
  • Board and management information
  • ESG and sustainability information

Investor relations contact

John M. Edminson — CFO
EXACT Therapeutics
john.edminson@exact-tx.com